Clik here to view.
Sanofi Badly Needs The Genzyme Deal
One reason for the progress in SanofiAventis’ talks to take over Genzyme is that Sanofi’s need for new drugs is getting ever more urgent. CEO Chris Viebacher badly needs new products. A breast cancer...
View ArticleClik here to view.
The Dubious Science Of Shaken-Baby Syndrome
Image via Wikipedia The medical profession likes to dress up what it does as rigorous science. Doctors publish papers in fancy journals using fancy jargon and fancy statistics. Too often there is...
View ArticleClik here to view.
$100,000 Cancer Drugs, Ineffective $50,000 Back Operations, Unnecessary MRI...
Image via Wikipedia This post kicks off a Forbes conversation on health costs that will appear online over the next few days. David Whelan, other Forbes contributors, and I will be debating how...
View ArticleA Dying Cancer Patient’s Plea For Personalized Medicine
I’ve known Adriana Jenkins for years in her PR role for various biotech companies. What I didn’t know much about was her long battle with breast cancer, which she describes below. She says that a...
View ArticleClik here to view.
The $15 Billion Biotech Blockbuster Whose Sales Are Going Up With No End In...
Image via Wikipedia Quiz: What nearly 100 year old injected drug has sales are over $15 billion that are growing rapidly with no end in sight, even as competing pill drugs are plagued by safety...
View ArticleClik here to view.
Avik Roy’s Health Cost Fantasy
Countries with universal health care Forbes commentator Avik Roy says that I traffic in bromides and conventional wisdom in my post on soaring health costs from $100,00 cancer drugs and ineffective...
View ArticleClik here to view.
The Next Big Move For The Smartest Biotech Investor
Randal J. Kirk, worth $2.2 billion, is one of the only billionaires to make his money from biotech. He may just be the best biotech investor ever. He made $1.2 billion when he sold his New River...
View ArticleClik here to view.
End Of An Era: The Last Herper-Langreth Biotech Story
Image via Wikipedia This profile of billionaire biotech investor Randal J. Kirk will appear in the March 14 issue of Forbes Magazine. It discusses his new synthetic biology company that will compete...
View ArticleClik here to view.
My Favorite Forbes Biotech Stories
After 11 incredible years at Forbes, I’m leaving for a competitor owned by a billionaire. There have been so many stories over the years on companies ranging from Amgen to Genentech to Merck to Pfizer....
View ArticleClik here to view.
The Best And Worst of Forbes’ Langreth and Herper
It’s the end of an era. I’m leaving Forbes today after 11 years. It is hard to believe. For about seven of those years, I’ve worked closely with Matt Herper, who taught me much of what I know about the...
View Article
